CA2663041A1 - Method of enhancing mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes - Google Patents

Method of enhancing mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes Download PDF

Info

Publication number
CA2663041A1
CA2663041A1 CA002663041A CA2663041A CA2663041A1 CA 2663041 A1 CA2663041 A1 CA 2663041A1 CA 002663041 A CA002663041 A CA 002663041A CA 2663041 A CA2663041 A CA 2663041A CA 2663041 A1 CA2663041 A1 CA 2663041A1
Authority
CA
Canada
Prior art keywords
chor8
lower alkyl
independently
ch2or8
ch2ch2o
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002663041A
Other languages
English (en)
French (fr)
Inventor
Michael R. Johnson
Richard C. Boucher
Andrew J. Hirsch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Parion Sciences Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2663041A1 publication Critical patent/CA2663041A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA002663041A 2006-09-07 2007-09-07 Method of enhancing mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes Abandoned CA2663041A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US84266906P 2006-09-07 2006-09-07
US60/842,669 2006-09-07
US84517106P 2006-09-18 2006-09-18
US60/845,171 2006-09-18
PCT/US2007/077880 WO2008031028A2 (en) 2006-09-07 2007-09-07 Methods of enhancing mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes

Publications (1)

Publication Number Publication Date
CA2663041A1 true CA2663041A1 (en) 2008-03-13

Family

ID=39158091

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002663041A Abandoned CA2663041A1 (en) 2006-09-07 2007-09-07 Method of enhancing mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes

Country Status (12)

Country Link
US (1) US8058278B2 (https=)
EP (1) EP2059237A4 (https=)
JP (1) JP2010502738A (https=)
KR (1) KR20090065508A (https=)
AR (1) AR062741A1 (https=)
AU (1) AU2007294547A1 (https=)
BR (1) BRPI0716884A2 (https=)
CA (1) CA2663041A1 (https=)
EA (1) EA200970258A1 (https=)
MX (1) MX2009002602A (https=)
TW (1) TW200817343A (https=)
WO (1) WO2008031028A2 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
WO2004073729A1 (ja) 2003-02-21 2004-09-02 Translational Research Ltd. 薬物の経鼻投与用組成物
CA2519287A1 (en) 2003-03-27 2004-10-14 Bioactis Limited Powder medicine applicator for nasal cavity
ES2432529T3 (es) * 2003-08-18 2013-12-04 Parion Sciences, Inc. Bloqueadores del canal de sodio de pirazinoilguanidina rematada
WO2006016530A1 (ja) * 2004-08-10 2006-02-16 Translational Research, Ltd. 速効性でかつ高い吸収性を可能とする経鼻投与用組成物
US7399766B2 (en) * 2004-08-18 2008-07-15 Parion Sciences, Inc. Soluble amide & ester pyrazinoylguanidine sodium channel blockers
US7807834B2 (en) * 2005-08-03 2010-10-05 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
WO2007146867A2 (en) * 2006-06-09 2007-12-21 Parion Sciences Inc. Aliphatic pyrazinoylguanidine sodium channel blockers with beta agonist activity
PL2035004T3 (pl) * 2006-06-09 2013-01-31 Parion Sciences Inc Podstawione fenylem pirazynoiloguanidynowe blokery kanału sodowego o aktywności beta-agonistycznej
WO2008031048A2 (en) * 2006-09-07 2008-03-13 Parion Sciences, Inc. Enhanced mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes
CN101668544B (zh) 2006-12-26 2013-04-24 株式会社新日本科学 经鼻投用制剂
US8288391B2 (en) * 2007-04-03 2012-10-16 Parion Sciences, Inc. Pyrazinoylguanidine compounds for use as taste modulators
WO2008124496A1 (en) * 2007-04-03 2008-10-16 Parion Sciences, Inc. Method of treating acid-sensing ion channel mediated pain, cough, and central nervous system disorders
DE102007040615A1 (de) * 2007-08-27 2009-03-05 Bitop Ag Osmolyte zur Behandlung von allergisch oder viral bedingten Atemwegserkrankungen
CA2702094C (en) 2007-10-10 2018-05-01 Parion Sciences, Inc. Delivering osmolytes by nasal cannula
DE102007052380A1 (de) * 2007-10-31 2009-05-07 Bitop Ag Osmolythaltige Zubereitungen zur Anwendung bei trockenen Schleimhäuten
ES2485642T3 (es) 2008-02-26 2014-08-14 Parion Sciences, Inc. Bloqueantes poli-aromáticos de los canales de sodio
WO2009126695A2 (en) * 2008-04-08 2009-10-15 Dynamis Therapeutics, Inc. Method for treating or preventing dry eye disorders using alkylamino-polyhydroxyalkanes
US20100074881A1 (en) * 2008-07-11 2010-03-25 Parion Sciences, Inc. Multiple nebulizer systems
US9101539B2 (en) * 2009-05-15 2015-08-11 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
GB2472327B (en) 2009-07-31 2013-03-13 Shin Nippon Biomedical Lab Ltd Intranasal granisetron and nasal applicator
EP2717855A4 (en) 2011-06-07 2014-11-12 Parion Sciences Inc Methods of Treatment
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
CN103687488B (zh) 2011-06-27 2015-06-10 帕里昂科学公司 化学和代谢稳定的具有钠通道阻滞剂活性的二肽
HUE039734T2 (hu) 2012-05-29 2019-01-28 Parion Sciences Inc Nátriumcsatorna-blokkoló aktivitású, dendrimerszerû amino-amid-származékok száraz szem és más nyálkahártya-megbetegedések kezelésére
WO2014036445A2 (en) * 2012-08-31 2014-03-06 Johnson Michael R Novel mucolytic agents
CA2894279A1 (en) * 2012-12-07 2014-06-12 Paul Boucher Nasal cannula for delivery of aerosolized medicaments
CN108658876A (zh) 2012-12-17 2018-10-16 帕里昂科学公司 3,5-二氨基-6-氯-n-(n-(4-苯基丁基)甲脒基)吡嗪-2-甲酰胺化合物
ES2674665T3 (es) * 2012-12-17 2018-07-03 Parion Sciences, Inc. Compuestos de 3,5-diamino-6-cloro-N-(N-(4-fenilbutilo)carbamimidoilo)-pirazina-2-carboxamida
CA2895512C (en) 2012-12-17 2021-10-19 Parion Sciences, Inc. Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration
MX368243B (es) 2013-08-23 2019-09-25 Parion Sciences Inc Agentes mucolíticos de ditiol.
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
US20150376145A1 (en) 2014-06-30 2015-12-31 Parion Sciences, Inc. Stable sodium channel blockers
CA2974210A1 (en) 2015-01-30 2016-08-04 Parion Sciences, Inc. Novel monothiol mucolytic agents
CA2984424A1 (en) 2015-04-30 2016-11-03 Parion Sciences, Inc. Novel prodrugs of dithiol mucolytic agents
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4501729A (en) 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
AU654979B2 (en) 1990-10-05 1994-12-01 University Of North Carolina At Chapel Hill, The Method of administering amiloride
AUPM411494A0 (en) 1994-02-25 1994-03-24 Central Sydney Area Health Service Method and device for the provocation of upper or lower airway narrowing and/or the induction of sputum
US5656256A (en) 1994-12-14 1997-08-12 The University Of North Carolina At Chapel Hill Methods of treating lung disease by an aerosol containing benzamil or phenamil
EP1143896B1 (en) 1998-10-20 2006-12-13 The University of North Carolina at Chapel Hill Methods of hydrating the nasal mucosal surface
US6926911B1 (en) 1998-12-22 2005-08-09 The University Of North Carolina At Chapel Hill Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
KR20020038694A (ko) 1999-07-19 2002-05-23 프란시스 제이 메이어 소듐 채널 차단제의 콘쥬게이트 및 그 이용방법
WO2001055390A1 (en) 2000-01-28 2001-08-02 Human Genome Sciences, Inc. Human serpin polynucleotides, polypeptides, and antibodies
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US6858614B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenolic guanidine sodium channel blockers
US6903105B2 (en) 2003-02-19 2005-06-07 Parion Sciences, Inc. Sodium channel blockers
JP2007502829A (ja) 2003-08-18 2007-02-15 パリオン・サイエンシィズ・インコーポレーテッド 環状ピラジノイルグアニジンナトリウムチャネルブロッカー
ES2432529T3 (es) 2003-08-18 2013-12-04 Parion Sciences, Inc. Bloqueadores del canal de sodio de pirazinoilguanidina rematada
US7375107B2 (en) 2003-08-18 2008-05-20 Parion Sciences, Inc. Alaphatic pyrazinoylguanidine sodium channel blockers
US20050090505A1 (en) 2003-08-18 2005-04-28 Johnson Michael R. Methods of reducing risk of infection from pathogens
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
US7399766B2 (en) 2004-08-18 2008-07-15 Parion Sciences, Inc. Soluble amide & ester pyrazinoylguanidine sodium channel blockers
US7807834B2 (en) 2005-08-03 2010-10-05 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
WO2008031048A2 (en) * 2006-09-07 2008-03-13 Parion Sciences, Inc. Enhanced mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes

Also Published As

Publication number Publication date
EP2059237A2 (en) 2009-05-20
MX2009002602A (es) 2009-05-28
WO2008031028A3 (en) 2008-11-13
WO2008031028A2 (en) 2008-03-13
KR20090065508A (ko) 2009-06-22
BRPI0716884A2 (pt) 2013-10-15
AU2007294547A2 (en) 2009-03-19
EA200970258A1 (ru) 2009-08-28
TW200817343A (en) 2008-04-16
US20080090841A1 (en) 2008-04-17
EP2059237A4 (en) 2010-06-30
AR062741A1 (es) 2008-12-03
JP2010502738A (ja) 2010-01-28
AU2007294547A1 (en) 2008-03-13
US8058278B2 (en) 2011-11-15

Similar Documents

Publication Publication Date Title
US8058278B2 (en) Methods of enhancing mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes
US7981898B2 (en) Methods of enhancing mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes
US10159672B2 (en) Chemically and metabolically stable dipeptide possessing potent sodium channel blocker activity
US8124607B2 (en) Poly aromatic pyrazinoylguanidine sodium channel blockers
US7317013B2 (en) Cyclic pyrazinoylguanidine sodium channel blockers
US9856224B2 (en) Stable sodium channel blockers
US20110003832A1 (en) NEW CAPPED Pyrazinoylguanidine SODIUM CHANNEL BLOCKERS
AU2004271945A1 (en) Aliphatic pyrazinoylguanidine sodium channel blockers
CN101534813A (zh) 通过使用钠通道阻断剂和渗透调节剂的治疗来增加粘膜水化和粘液清除的方法
AU2013200821B2 (en) Heteroaromatic pyrazinoylguanidine sodium channel blockers

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20141210